A novel biomaterial for osteotropic drug nanocarriers: Synthesis and biocompatibility evaluation of a PLGA-ALE conjugate

Nanomedicine

Volumn 4, Issue 2, 2009, Pages 161-175

  Pignatello, Rosario ^a   Cenni, Elisabetta ^b   Micieli, Dorotea ^a   Fotia, Caterina ^b   Salerno, Manuela ^b   Granchi, Donatella ^b   Avnet, Sofia ^b   Sarpietro, Maria G ^a   Castelli, Francesco ^a   Baldini, Nicola ^b,c  

^a UNIVERSITY OF CATANIA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Alendronate; Biocompatibility; Bisphosphonates; Nanoparticles; ODDS; Osteotropic drug delivery systems; Poly(lactide co glycolide); Polymer conjugates

Indexed keywords

ALENDRONIC ACID; BIOMATERIAL; HYDROXYAPATITE; NANOCARRIER; NANOPARTICLE; POLYGLACTIN; SOLVENT;

ADSORPTION; ARTICLE; BIOCOMPATIBILITY; BLOOD CLOTTING; BLOOD COMPATIBILITY; CONJUGATE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; EVAPORATION; GAMMA IRRADIATION; HEMOLYSIS; HUMAN; HUMAN CELL; INSTRUMENT STERILIZATION; OSTEOBLAST; PARTICLE SIZE; PRIORITY JOURNAL; TRABECULAR BONE;

ALENDRONATE; BIOCOMPATIBLE MATERIALS; CELLS, CULTURED; DRUG CARRIERS; HUMANS; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR STRUCTURE; NANOPARTICLES; POLYGLYCOLIC ACID; POLYMERS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 67649911249     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/17435889.4.2.161     Document Type: Article

References (43)

1. Lu W, Sun Q, Wan J, She Z, Jiang XG: Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res. 66, 11878-11887 (2006).
2. Mitra A, Nan A, Line BR, Ghandehari H: Nanocarriers for nuclear imaging radiotherapy of cancer. Curr. Pharm. Des. 12, 4729-4749 (1995).
3. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R: Biodegradable long-circulating polymeric nanospheres. Science 263, 1600-1603 (1994).
4. Zimmer A, Kreuter J: Microspheres and nanoparticles used in ocular delivery systems. Adv. Drug Deliv. Rev. 16, 61-73 (1995).
5. Langer R: Drug delivery and targeting. Nature 392, 5-10 (1998).
6. Bala I, Hariharan S, Ravi Kumar MNV: PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst. 2, 387-422 (2004).
7. Okada H: One and three-month release injectable microspheres of LH-RH superagonist leuprorelin acetate. Adv. Drug Deliv. Rev. 28, 43-70 (1997).
8. Crivellari D, Pagani O, Veronesi A et al.: International Breast Cancer Study Group. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann. Oncol. 12, 353-356 (2001).
9. Greish K: Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target. 15, 457-464 (2007).
10. Hirabayashi H, Fujisaki J: Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents. Clin. Pharmacokinet. 42, 1319-1330 (2003).
11. Wang D, Miller SC, Kopeckova P, Kopecek J: Bone-targeting macromolecular therapeutics. Adv. Drug Del. Rev. 57, 1049-1076 (2005).
12. Niemi R, Vepsalainen J, Taipale H, Jarvinen T: Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel acyloxyalkyl esters of clodronic acid. J. Med. Chem. 42, 5053-5058 (1999).
13. Ezra A, Hoffman A, Breuer E et al.: A peptide prodrug approach for improving bisphosphonate oral absorption. J. Med. Chem. 43, 3641-3652 (2000).
14. Hirabayasbi H, Takahashi T, Fujisaki J et al.: Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS). J. Control. Rel. 70, 183-191 (2001).
15. Wright JE, Gittens SA, Bansal G et al.: A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages. Biomaterials 27, 769-784 (2006).
16. Gittens SA, Bansal G, Zernicke RF, Uludag H: Designing proteins for bone targeting. Adv. Drug Deliv. Rev. 57, 1011-1036 (2005).
17. Ogawa K, Mukai T, Inoue Y, Ono M, Saji H: Development of a novel 99mTc-chelate conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J. Nucl. Med. 47, 2042-2047 (2006).
18. Barrett J, Worth E, Bauss F, Epstein S: Ibandronate: a clinical pharmacological and pharmacokinetic update. J. Clin. Pharmacol. 44, 951-965 (2004).
19. Hengst V, Oussoren C, Kissel T, Storm G: Bone targeting potential of bisphosphonate targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int. J. Pharm. 331, 224-227 (2007).
20. Von Knoch F, Jaquiery C, Kowalsky M et al.: Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 26, 6941-6949 (2005).
21. Tosi G, Rivasi F, Gandolfi F, Costantino L, Vandelli MA, Forni F: Conjugated poly(D,L-co-glycolide) for the preparation of in vivo detectable nanoparticles. Biomaterials 26, 4189-4195 (2005).
22. Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunological criteria. J. Clin. Invest. 52, 2745-2756 (1973).
23. Di Silvio L, Gurav N: Osteoblasts. Human Cell Culture (Volume V, Chapter 11). Kluwer, UK (2001).
24. Choi SW, Kim JH: Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. J. Control. Rel. 122, 24-30 (2007).
25. Noel TR, Parker R, Ring SG, Tatham AS: The glass-transition behaviour of wheat gluten proteins. Int. J. Biol. Macromol. 17, 81-85 (1995).
26. Petrie SEB: Thermal behavior of annealed glasses. J. Polym. Sci. 10, 1255-1272 (1972).
27. McKenna GB: Comprehensive Polymer Science (Volume 1). Pergamon Press, Oxford, UK (1988).
28. Astete CE, Sabliov CM: Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed. 17, 247-289 (2006).
29. Bala I, Hariharan S, Kumar MN: PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst. 21, 387-422 (2004).
30. Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli MA, Forni F: Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Control. Rel. 108, 84-96 (2005).
31. Cutright DE, Perez B, Beasley JD 3rd, Larson WJ, Posey WR: Degradation rates of polymers and copolymers of polylactic and polyglycolic acids. Oral Surg. Oral Med. Oral Pathol. 37, 142-152 (1974).
32. Lin JH: Bisphosphonates: a review of their pharmacokinetic properties. Bone 18, 75-85 (1996).
33. Liu X-M, Wiswall AT, Rutledge JE et al.: Osteotropic β-cyclodextrin for local bone regeneration. Biomaterials 29, 1686-1692 (2008).
34. Blanco-Prieto MJ, Campanero MA, Besseghir K, Heimgatner F, Gander B: Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres. J. Control. Rel. 96, 437-448 (2004).
35. Wang D, Miller S, Sima M, Kopeckova P, Kopecek J: Synthesis and evaluation of water soluble polymeric bone-targeted drug delivery systems. Bioconj. Chem. 14, 853-859 (2003).
36. Rodriguez-Lorenzo V, Fernandez M, Parra J, Vasquez B, Lopez-Bravo A, San Roman J: Novel N-bisphosphonate based drug delivery systems: synthesis and preparation of targeting vehicles. Presented at: 20th European Conference on Biomaterials. Nantes, France, 27 September-1 October 2006.
37. Hansen MB, Nielsen SE, Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119, 203-210 (1989).
38. Low SP, Williams KA, Canham LT, Voelcker NH: Evaluation of mammalian cell adhesion on surface-modified porous silicon. Biomaterials 27, 4538-4546 (2006).
39. Sousa SR, Lamghari M, Sampaio P, Moradas-Ferreira P, Barbosa MA: Osteoblast adhesion and morphology on TiO2 depends on the competitive preadsorption of albumin and fibronectin. J. Biomed. Mater. Res. A 84, 281-290 (2008).
40. Liu XM, Lee HT, Reinhardt RA, Marky LA, Wang D: Novel biomineral-binding cyclodextrins for controlled drug delivery in the oral cavity. J. Control. Release 122, 54-62 (2007).
41. Nalwa HS, Webster T (Eds): Cancer nanotechnology - Nanomaterials for cancer diagnosis and therapy. American Scientific Publishers, Valencia, CA, USA (2006).
42. Bondì ML, Craparo EF, Giammona G et al.: Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies. Drug Deliv. 14, 61-67 (2007).
43. Pridgen EM, Langer R, Farokhzad OC: Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomed. 2, 669-680 (2007).